Baird analyst Joel Beatty initiated coverage of Sage Therapeutics with a Neutral rating and $15 price target. After the launch of Zurzuvae for the treatment of postpartum depression in December, the firm projects the company’s sales slowly but steadily growing to $262M in 2029, the analyst tells investors in a research note. Baird is also modeling a 20% probability of success to both dalzanemdor for Huntington’s disease and SAGE-324 for essential tremor, the firm added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAGE:
- Sage CEO tells Bloomberg ‘lot of inbound interest’ on Huntington’s drug
- Novel Postpartum Depression Treatment Offers Upside Potential for Sage Therapeutics (NASDAQ:SAGE)
- Sage Therapeutics price target lowered to $25 from $28 at H.C. Wainwright
- Sage Therapeutics price target lowered to $15 from $26 at RBC Capital
- Sage Therapeutics price target lowered to $17 from $21 at Canaccord